We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+212.2%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$456M
AUM Growth
+$209M
Cap. Flow
+$8.86M
Cap. Flow %
1.94%
Top 10 Hldgs %
77.4%
Holding
26
New
2
Increased
8
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$19.7M
2
DYN icon
Dyne Therapeutics
DYN
+$13.9M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$12.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$11.2M
5
ABVX
Abivax
ABVX
+$11M

Top Sells

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$28.5M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$13.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$7.31M
4
ASND icon
Ascendis Pharma A/S
ASND
+$6.59M
5
ARGX icon
argenx
ARGX
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTNM
26
Contineum Therapeutics
CTNM
$566M
– –
-319,348
Closed -$1.27M
1
2

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Saturn V Capital Management held 26 positions worth $456M, up 85% from $247M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Saturn V Capital Management's Q3 2025 filing shows 2 new, 8 increased, 7 reduced and 9 closed positions. Its largest new stake was Pharvaris: 886,332 shares worth $22.1M. The largest sale was Celcuity, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Saturn V Capital Management's largest Q3 2025 buy was Pharvaris: 886,332 shares worth $22.1M.
  • Saturn V Capital Management added most to Dyne Therapeutics in Q3 2025, an estimated $13.9M increase.
  • Saturn V Capital Management's biggest Q3 2025 reduction was Celcuity, cutting an estimated $28.5M.
  • Saturn V Capital Management fully exited MoonLake Immunotherapeutics in Q3 2025, selling an estimated $13.7M.
  • Saturn V Capital Management's ten largest holdings make up 77% of its $456M portfolio in Q3 2025.
  • Saturn V Capital Management opened 2 new positions and closed 9 in Q3 2025.
  • Saturn V Capital Management's portfolio value rose 85% quarter-over-quarter to $456M.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.